^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    volrustomig (MEDI5752)

    i
    Other names: MEDI5752, MEDI-5752, MEDI 5752
    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    2d
    Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer (clinicaltrials.gov)
    P2, N=38, Recruiting, University of Chicago | Suspended --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • volrustomig (MEDI5752)
    18d
    Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer (clinicaltrials.gov)
    P2, N=38, Suspended, University of Chicago | Initiation date: Jan 2026 --> Oct 2025 | Not yet recruiting --> Suspended
    Trial initiation date • Trial suspension
    |
    carboplatin • paclitaxel • volrustomig (MEDI5752)
    18d
    Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody. (PubMed, Clin Cancer Res)
    These results support further development of volrustomig as monotherapy and in combination regimens, with phase 3 trials ongoing.
    P1 data • PK/PD data • Journal • First-in-human
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    volrustomig (MEDI5752)
    1m
    Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (clinicaltrials.gov)
    P3, N=800, Recruiting, AstraZeneca | Trial completion date: Oct 2029 --> Sep 2030 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    volrustomig (MEDI5752)
    2ms
    A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    volrustomig (MEDI5752)
    3ms
    eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P3, N=1200, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • PD-L1 negative • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)
    3ms
    The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities. (PubMed, Cancer Med)
    Since the first BsAb approval in 2014, the field has rapidly expanded, with solid tumor oncology advancing dynamically. The major focus has been on combining BsAbs with immunotherapy strategies, followed by targeting known oncogenic pathways. The shift toward biotechnology-led innovation underscores the growing therapeutic and financial interest in this field. Optimizing the efficacy and safety of these molecules is key to paving the way for the next era of immune and precision oncology.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase)
    |
    HER-2 positive
    |
    Rybrevant (amivantamab-vmjw) • Kaitanni (cadonilimab) • Yidafan (ivonescimab) • volrustomig (MEDI5752)
    4ms
    eVOLVE-RCC02: A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC (clinicaltrials.gov)
    P3, N=1116, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • volrustomig (MEDI5752) • casdatifan (AB521)
    4ms
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=825, Recruiting, AstraZeneca | Trial completion date: Mar 2028 --> Nov 2028 | Trial primary completion date: Mar 2027 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)
    4ms
    GEMINI-Hepatobiliary: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)
    P2, N=294, Recruiting, AstraZeneca | Trial completion date: Dec 2026 --> Oct 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    4ms
    eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=110, Recruiting, AstraZeneca | N=257 --> 110
    Enrollment change
    |
    cisplatin • carboplatin • paclitaxel • volrustomig (MEDI5752)
    5ms
    Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov)
    P2, N=413, Recruiting, AstraZeneca | Trial completion date: Jul 2026 --> Jun 2027 | Trial primary completion date: Jul 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)